Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 27, 2022 (4 years ago)

Tobramycin 660mg in Ns 66ml

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of sterility assurance

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

TOBRAMYCIN 660MG IN NS 66ML, antibiotic, Rx Only, use with homepump, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320,

Drug: Tobramycin

Recalling firm
Sentara Infusion Services
Origin
VA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0317-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Tobramycin recalls

See all
Class II · Moderate risk

Tobramycin for Injection

Failed Stability Specification: Water determination was found not complying with specification.

Terminated Stability / shelf life Eugia US LLC NDC 55150-470-06 D-0385-2024

Other recalls by Sentara Infusion Services

All 2022 recalls